An Open-Label Phase 1b/2 Study to Assess Safety and Target Engagement of E2814 in Subjects With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
Latest Information Update: 25 Jul 2024
At a glance
- Drugs E 2814 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Inc
- 22 Jul 2024 Status changed from recruiting to completed.
- 29 Nov 2023 Planned End Date changed from 22 Apr 2025 to 14 Jul 2025.
- 29 Nov 2023 Planned primary completion date changed from 22 Apr 2025 to 14 Jul 2025.